According to the agreement terms, Haisco will receive licensing fees for the HSK42360 and HSK39297 projects from Nuvectis, including a deposit of $40 million, recent milestone payments, and additional milestone payments up to $1.421 billion, as well as royalties based on the net sales of future products reaching double-digit levels.

 HSK42360 is a proprietary BRAF paradoxical breaker inhibitor developed by Hisicore, which inhibits the BRAF V600X mutation while blocking BRAF dimerization. This allows it to overcome acquired resistance observed with first-generation BRAF inhibitors in various cancer treatments. The molecule has good penetration into the central nervous system and shows strong potential therapeutic benefits in primary brain tumors and brain metastases. Currently, HSK42360 is undergoing phase I clinical studies.

 HSK39297 is a highly efficient small molecule inhibitor of the complement B factor (FB) by Haisco, independently developed by Haisco. It inhibits the activation of the alternative pathway (AP) and the complement amplification cycle by suppressing the activity of FB, thereby reducing the activity of the entire complement pathway. Its purpose is to treat various diseases mediated by abnormal complement activation. Currently, HSK39297 has submitted a new drug application (NDA) for the PNH indication in China, and phase II clinical trials for patients with lupus nephritis and phase III clinical studies for primary IgA nephropathy are underway.

 The signing of this agreement will further advance Hisco’s goals of developing and commercializing licensed products worldwide. This move is in line with Hisco’s overall development strategy focused on internationalization and innovation-driven growth, and represents an important step in enhancing Hisco’s global presence and accelerating the transformation of innovation achievements.

About Nuvectis

Nuvectis is a clinical-stage biopharmaceutical company based in the United States. It focuses on developing innovative precision medicine drugs for diseases with significant unmet medical needs in areas such as cancer and immunology. Nuvectis is committed to discovering, developing, and commercializing innovative therapies with unique mechanisms and clinical value, in order to improve treatment outcomes for cancer patients.

About Haisco

Hisicor is a professional pharmaceutical group listed company focused on new drug research and development, integrating production, manufacturing, and sales promotion (stock code: 002653.SZ). Since its establishment in 2000, Hisicor Pharmaceutical Group has always aimed to become the most trusted international pharmaceutical enterprise. It focuses on five major disease areas including anesthesia and analgesia, chronic metabolic diseases, respiration, autoimmune diseases, and tumors. Through innovation-driven strategies and a global approach, it strives to build a world-class research and development innovation system. Currently, Hisicor Pharmaceutical Group has developed a range of diversified research and development projects with independent intellectual property rights, covering small molecule innovative drugs, biopharmaceuticals, and high-end generic drugs. Many projects are in the clinical development stage, and several innovative drugs have already been commercialized, providing diverse innovative product solutions to the world.